DK0823889T3 - 1,3-propandiolderivater som bioaktive forbindelser - Google Patents

1,3-propandiolderivater som bioaktive forbindelser

Info

Publication number
DK0823889T3
DK0823889T3 DK96912139T DK96912139T DK0823889T3 DK 0823889 T3 DK0823889 T3 DK 0823889T3 DK 96912139 T DK96912139 T DK 96912139T DK 96912139 T DK96912139 T DK 96912139T DK 0823889 T3 DK0823889 T3 DK 0823889T3
Authority
DK
Denmark
Prior art keywords
bioactive compounds
propanediol derivatives
propanediol
derivatives
bioactive
Prior art date
Application number
DK96912139T
Other languages
Danish (da)
English (en)
Inventor
David F Horrobin
Mehar Manku
Austin Mcmordie
Philip Knowles
Peter Redden
Andrea Pitt
Paul Bradley
Paul Wakefield
Original Assignee
Scarista Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9508823.3A external-priority patent/GB9508823D0/en
Priority claimed from GBGB9517107.0A external-priority patent/GB9517107D0/en
Priority claimed from GBGB9605440.8A external-priority patent/GB9605440D0/en
Application filed by Scarista Ltd filed Critical Scarista Ltd
Application granted granted Critical
Publication of DK0823889T3 publication Critical patent/DK0823889T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/36—[b, e]-condensed, at least one with a further condensed benzene ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychology (AREA)
DK96912139T 1995-05-01 1996-05-01 1,3-propandiolderivater som bioaktive forbindelser DK0823889T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9508823.3A GB9508823D0 (en) 1995-05-01 1995-05-01 Drug Derivatives
GBGB9517107.0A GB9517107D0 (en) 1995-08-21 1995-08-21 Fatty acid esters
GBGB9605440.8A GB9605440D0 (en) 1996-03-15 1996-03-15 Presentaion of bioactives
PCT/GB1996/001053 WO1996034846A1 (en) 1995-05-01 1996-05-01 1,3-propane diol derivatives as bioactive compounds

Publications (1)

Publication Number Publication Date
DK0823889T3 true DK0823889T3 (da) 2003-01-27

Family

ID=27267691

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96912139T DK0823889T3 (da) 1995-05-01 1996-05-01 1,3-propandiolderivater som bioaktive forbindelser
DK96912138T DK0823895T3 (da) 1995-05-01 1996-05-01 Fedtsyreestere som bioaktive forbindelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK96912138T DK0823895T3 (da) 1995-05-01 1996-05-01 Fedtsyreestere som bioaktive forbindelser

Country Status (29)

Country Link
US (4) USRE43632E1 (sk)
EP (2) EP0823895B1 (sk)
JP (3) JP3960481B2 (sk)
KR (2) KR19990008243A (sk)
AR (1) AR004483A1 (sk)
AT (2) ATE224353T1 (sk)
AU (2) AU713858B2 (sk)
BG (2) BG63892B1 (sk)
BR (2) BR9606604A (sk)
CA (2) CA2218699C (sk)
CZ (2) CZ297646B6 (sk)
DE (2) DE69623764T2 (sk)
DK (2) DK0823889T3 (sk)
EE (2) EE9700281A (sk)
ES (2) ES2224166T3 (sk)
HK (1) HK1003882A1 (sk)
HU (2) HUP9802384A3 (sk)
IL (1) IL118061A (sk)
IS (2) IS4603A (sk)
MY (2) MY118354A (sk)
NO (2) NO975035L (sk)
NZ (2) NZ306509A (sk)
PL (2) PL323176A1 (sk)
PT (2) PT823895E (sk)
RU (1) RU2215733C2 (sk)
SI (2) SI0823889T1 (sk)
SK (2) SK147097A3 (sk)
TR (2) TR199701277T1 (sk)
WO (2) WO1996034855A1 (sk)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2328155B (en) * 1996-04-12 2000-08-02 Peptide Technology Pty Limited Methods of treating immunopathologies using polyunsaturated fattyacids
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5760083A (en) * 1996-08-07 1998-06-02 Wisconsin Alumni Research Foundation Use of CLA to reduce the incidence of valgus and varus leg deforomities in poultry
GB9622636D0 (en) * 1996-10-30 1997-01-08 Scotia Holdings Plc Presentation of bioactives
CZ326896A3 (cs) * 1996-11-07 1998-05-13 Milo Olomouc, A. S. Tuk se specifickými protisklerotickými účinky
GB9705102D0 (en) * 1997-03-12 1997-04-30 Scotia Holdings Inc Presentation of fatty acids
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
DE19718245C5 (de) * 1997-04-30 2004-11-11 Cognis Deutschland Gmbh & Co. Kg Synthetische Triglyceride auf Basis konjugierter Linolsäure, Verfahren zu deren Herstellung und deren Verwendung
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6019990A (en) * 1997-11-21 2000-02-01 Natural Nutrition Ltd. As Conjugated linoleic acid delivery system in cosmetic preparations
US6136985A (en) * 1997-12-23 2000-10-24 Dcv, Inc. CLA esters and uses thereof
JPH11209279A (ja) * 1998-01-05 1999-08-03 Natural Ltd As 体重減少および肥満処置の方法
ES2201673T3 (es) * 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US20020002154A1 (en) * 1998-02-11 2002-01-03 Pol-Henri Guivarc'h Method and composition for treatment of inflammatory conditions
GB9804361D0 (en) * 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
ATE350028T1 (de) 1998-03-17 2007-01-15 Natural Asa Konjugierte linolsäurezusammensetzung
US6015833A (en) 1998-03-17 2000-01-18 Conlinco., Inc. Conjugated linoleic acid compositions
US7776353B1 (en) 1998-03-17 2010-08-17 Aker Biomarine Asa Conjugated linoleic acid compositions
US6177580B1 (en) 1998-04-21 2001-01-23 Henkel Kommanditgesellschaft Auf Aktien Conjugated linolenic acid-based synthetic triglycerides
US7101914B2 (en) 1998-05-04 2006-09-05 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6696584B2 (en) 1998-05-04 2004-02-24 Natural Asa Isomer enriched conjugated linoleic acid compositions
US6060514A (en) * 1998-05-04 2000-05-09 Conlin Co., Inc. Isomer enriched conjugated linoleic acid compositions
US6214372B1 (en) 1998-05-04 2001-04-10 Con Lin Co., Inc. Method of using isomer enriched conjugated linoleic acid compositions
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6132582A (en) 1998-09-14 2000-10-17 The Perkin-Elmer Corporation Sample handling system for a multi-channel capillary electrophoresis device
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
GB9918028D0 (en) * 1999-07-30 1999-09-29 Unilever Plc Skin care composition
GB9927629D0 (en) * 1999-11-24 2000-01-19 Croda Int Plc Compounds
AU2001251449B2 (en) 2000-04-06 2005-04-07 Conlinco, Inc. Conjugated linoleic acid compositions
JP5258134B2 (ja) 2000-04-18 2013-08-07 エイカー バイオマリン アーエスアー 共役リノール酸粉末
US6380409B1 (en) 2000-04-24 2002-04-30 Conlin Co., Inc. Methods for preparing CLA isomers
US6927239B1 (en) * 2000-08-02 2005-08-09 Pharmanutrients Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
CA2442692A1 (en) * 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
DE60221287T4 (de) * 2001-11-08 2009-06-25 Atrium Medical Corp. Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US6677470B2 (en) 2001-11-20 2004-01-13 Natural Asa Functional acylglycerides
US6743931B2 (en) 2002-09-24 2004-06-01 Natural Asa Conjugated linoleic acid compositions
US20040106584A1 (en) * 2002-09-27 2004-06-03 Linda Arterburn Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US7074418B2 (en) * 2002-11-18 2006-07-11 Changaris David G Conjugated fatty acid based emulsion and methods for preparing and using same
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
MXPA05008216A (es) * 2003-01-31 2005-10-05 Procter & Gamble Medios para mejorar la apariencia del tejido queratinoso mamifero.
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
US7091369B2 (en) * 2003-07-15 2006-08-15 Board Of Trustees Operating Michigan State University Synthesis of polyconjugated fatty acids
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
CA2537865A1 (en) * 2003-08-05 2005-02-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neuroprotectin protects against cellular apoptosis, neuronal stroke damage, alzheimer's disease and retinal degeneration
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
US20050154059A1 (en) * 2004-01-13 2005-07-14 Cook Mark E. Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8263102B2 (en) * 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
JP2008522972A (ja) * 2004-12-06 2008-07-03 レリアント ファーマスーティカルズ インコーポレイテッド 脂肪酸エステルを有する安定性フェノフィブラート組成物
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
US20060211763A1 (en) * 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
US20060229366A1 (en) * 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8470861B2 (en) 2005-11-22 2013-06-25 University Of Rochester Mitochondria-targeted antioxidant prodrugs and methods of use
EP1954322A4 (en) * 2005-11-22 2010-11-17 Univ Rochester ANTIOXIDATION PRODRUGS AND METHOD OF APPLICATION TO THE MITOCHONDRIEN
JP2009523414A (ja) 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
EP1983975B1 (en) * 2006-02-03 2015-07-29 Giulio Cossu Method of treatment for muscular dystrophy
US20070275139A1 (en) * 2006-02-10 2007-11-29 Melissa Joerger Food compositions comprising renewably-based, biodegradable1,3-propanediol
JP2009532506A (ja) * 2006-02-10 2009-09-10 デユポン・テイト・アンド・ライル・バイオ・プロダクツ・カンパニー・エルエルシー 生物学的ベースの１，３−プロパンジオールのモノエステルおよびジエステルを含む組成物
US20070207113A1 (en) 2006-02-10 2007-09-06 Melissa Joerger Personal care and cosmetic compositions comprising renewably-based, biodegradable 1,3-propanediol
EP2081550B2 (en) 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
JP5099808B2 (ja) * 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
EP2083875B1 (en) 2006-11-06 2013-03-27 Atrium Medical Corporation Coated surgical mesh
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080176957A1 (en) * 2006-11-15 2008-07-24 Dupont Tate & Lyle Bio Products Company, Llc Preservative compositions comprising renewably-based, biodegradable 1,3-propanediol
US20090029944A1 (en) * 2007-06-19 2009-01-29 Skinner Keith K Methods for adding fatty acids to agents in aqueous solution to improve bioavailability
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
MX2011000273A (es) 2008-07-08 2011-05-23 Catabasis Pharmaceuticals Inc Salicilatos acetilados con acidos grasos y sus usos.
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
FR2940281B1 (fr) 2008-12-22 2011-04-01 Fabre Pierre Dermo Cosmetique Ester de diol et d'acide gras polyinsature comme agent anti-acne
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
SG10201500431SA (en) 2009-09-01 2015-03-30 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
RU2758369C2 (ru) 2009-09-23 2021-10-28 Амарин Фармасьютикалз Айрлэнд Лимитед Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
WO2011044138A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Lipoic acid acylated salicylate derivatives and their uses
KR102073938B1 (ko) 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
US20110212958A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid raloxifene derivatives and their uses
KR20130026428A (ko) * 2010-03-04 2013-03-13 아마린 파마, 인크. 심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
WO2011109681A1 (en) 2010-03-05 2011-09-09 Catabasis Pharmaceuticals, Inc. Fatty acid cox inhibitor derivatives and their uses
CN102843922B (zh) 2010-05-13 2015-12-16 尼特罗米加公司 硝基脂肪酸–认知减退的神经保护和/或抑制
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20140127289A1 (en) 2010-11-29 2014-05-08 Armarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
JP5941531B2 (ja) 2011-04-13 2016-06-29 イーエルシー マネージメント エルエルシー パーソナルケア組成物に適した温和なアニオン界面活性剤
US8568700B2 (en) 2011-04-13 2013-10-29 Elc Management, Llc Conditioning agents for personal care compositions
US8809560B2 (en) 2011-05-17 2014-08-19 Board Of Trustees Of The University Of Arkansas Trans-, trans-conjugated linoleic acid compositions and use thereof
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013068846A1 (en) 2011-11-09 2013-05-16 Pronova Biopharma Norge As Membrane-based processes for reducing at least one impurity and making a concentrate comprising at least one natural component from a marine fatty acid oil mixture, and compositions resulting thereof
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
TW201343203A (zh) 2011-12-22 2013-11-01 Pronova Biopharma Norge As 含有ω－３脂肪酸之經明膠／藻酸鹽延緩釋放型膠囊，其製法及用途
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
WO2013134482A1 (en) 2012-03-07 2013-09-12 Children's Medical Center Corporation Methods for enhancing, improving, or increasing fertility or reproductive function
EP2833881A1 (en) 2012-04-04 2015-02-11 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
AU2013257710B2 (en) * 2012-05-08 2016-10-20 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
AU2013277441B2 (en) 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
CA2873018A1 (en) * 2012-07-03 2014-01-09 Cellixbio Private Limited Compositions and methods for the treatment of moderate to severe pain
JP2014050781A (ja) * 2012-09-06 2014-03-20 Shiko Actec Kk 油煙含有排気用脱臭フィルタ
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9062276B2 (en) 2012-12-03 2015-06-23 Board Of Trustees Of The University Of Arkansas Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US20150182546A1 (en) * 2013-03-15 2015-07-02 Mitochondrial Concepts Llc Therapeutic agent for enhancing mitochondrial function
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015011724A2 (en) 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
CN103417507B (zh) * 2013-08-23 2015-12-02 王显著 布地奈德药物组合物
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2927675A1 (en) 2013-10-18 2015-04-23 Blanchette Rockefeller Neurosciences Institute Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
RU2016116835A (ru) 2013-11-05 2017-12-11 Хиллс Пет Нутришн, Инк. Способы и композиции для улучшения функции почек
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10208014B2 (en) * 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017019654A1 (en) * 2015-07-28 2017-02-02 The Lubrizol Corporation Seal swell agents for lubricating compositions
US9968531B2 (en) 2015-08-05 2018-05-15 Dupont Tate & Lyle Bio Products Company, Llc Deodorants containing 1,3-propanediol
KR101835860B1 (ko) 2015-10-30 2018-03-09 순천향대학교 산학협력단 난소암 또는 경계성 난소종양의 예방 또는 치료용 조성물 및 진단용 마커 조성물
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3028392A1 (en) * 2016-06-20 2017-12-28 The Scripps Research Institute Antimalarial compositions and uses thereof
FR3053252B1 (fr) * 2016-06-29 2020-04-24 Laboratoires Carilene Produit, ou agent actif, ou composition pour le soin des seins en periode pre-mensuelle ou menstruelle ou pour le soin de la symptomatologie des mastodynies
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US10052300B1 (en) * 2017-10-19 2018-08-21 David G. Changaris Methods and composition for suppression of deep seated fungal growth on skin
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102076314B1 (ko) * 2018-07-16 2020-02-11 (주) 에프엔지리서치 녹용에서 분리한 신규 화합물 및 이의 약학적 용도
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4306101A1 (en) 2022-07-14 2024-01-17 Gat Therapeutics S.L. Compositions comprising amarouciaxanthin a esters and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924528A (en) 1955-08-22 1960-02-09 Drew & Co Inc E F Synthetic hard butter
US2993063A (en) * 1956-12-17 1961-07-18 Colgate Palmolive Co Cocoa butter substitute and process of making same
CH366554A (de) 1957-10-10 1963-01-15 Montedison Spa Verfahren zur Herstellung von @-Amino-caprylsäure und ihren Estern
US3291816A (en) 1963-10-02 1966-12-13 Leo A Goldblatt Dehydration of lesquerolates
GB1135647A (en) 1965-06-29 1968-12-04 Grace W R & Co New esters
FR1782M (fr) * 1966-12-21 1963-04-22 Rech S Pharmacotechniques Soc Le nicotinate de cétyle comme antalgique et révulsif et les compositions pharmaceutiques pour son administration, notamment par voie percutanée.
DE1912486B1 (de) 1969-03-12 1970-03-19 Ruhrchemie Ag Schmiermittel auf der Basis von Carbonsaeureestern
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3989728A (en) 1975-02-12 1976-11-02 The Procter & Gamble Company Process for synthesizing specific complete mixed polyol esters
CH883475A4 (sk) 1975-07-07 1977-02-28
CA1079294A (en) 1975-07-31 1980-06-10 Takeshi Okano Process for producing alkylene glycol esters
IL59407A (en) * 1979-03-06 1983-12-30 Sanofi Sa Di-n-propylacetic acid diesters of glycerol,their preparation and pharmaceutical compositions containing them
US4268426A (en) * 1979-05-07 1981-05-19 Textron, Inc. Water-dispersible urethane polymers, aqueous polymer dispersions and half-esters useful therein
JPS5767511A (en) 1980-10-15 1982-04-24 Lion Corp Agent for imparting iridescent luster to cosmetic
US4469704A (en) 1980-12-26 1984-09-04 Ss Pharmaceutical Co., Ltd. 2,3-Butanediol diester derivatives, process for producing the same, and an antiulcer drug containing the same
DE3174885D1 (en) * 1981-02-03 1986-07-31 Ici Plc Process for the extraction of metal values and novel metal extractants
ATE22804T1 (de) 1982-03-01 1986-11-15 Efamol Ltd Pharmazeutische zusammensetzung.
IL67445A (en) * 1982-12-09 1985-11-29 Teva Pharma Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids
GR82658B (sk) * 1983-08-01 1985-02-07 Mclean Hospital Corp
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
DE3378040D1 (en) * 1983-10-28 1988-10-27 Alfred Bolz Apparatus for transporting objects by means of a liquid flowing in a pipe conduit
US4619938A (en) * 1984-03-21 1986-10-28 Terumo Kabushiki Kaisha Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
GB2161477B (en) 1984-03-30 1987-09-16 Unilever Plc Aliphatic esters of diols and compositions containing them
GB8412049D0 (en) * 1984-05-11 1984-06-20 Unilever Plc Treatment
GB8420771D0 (en) * 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
JPS61129190A (ja) * 1984-11-27 1986-06-17 Nippon Oil & Fats Co Ltd 重合性グリセロリン脂質
DE3443993A1 (de) 1984-12-01 1986-06-05 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von neuen indolderivaten und deren verwendung
FR2582000B1 (fr) 1985-05-14 1987-06-26 Oreal Esters gras bi ou tri-eniques d'erythromycine a, leur procede de preparation et compositions pharmaceutiques et cosmetiques les contenant
JPS62174060A (ja) 1985-10-11 1987-07-30 Terumo Corp ５−フルオロウラシル誘導体およびこれを含有する医薬製剤
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
EP0319126B1 (en) * 1987-10-14 1995-11-08 Kao Corporation Process for preparation of polyol fatty acid ester and glyceride mixture obtained
GB8729153D0 (en) * 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
JPH02129119A (ja) 1988-11-07 1990-05-17 Nippon Oil & Fats Co Ltd リポソーム製剤
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
CA2015946A1 (en) * 1989-06-27 1990-12-27 Lawrence P. Klemann Diol lipid analogues as edible fat replacements
US5008126A (en) 1989-06-27 1991-04-16 Nabisco Brands, Inc. Long chain diol diesters as low calorie fat mimetics
EP0510080A4 (en) * 1989-12-26 1992-12-02 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
JP2887617B2 (ja) 1990-08-17 1999-04-26 ミヨシ油脂株式会社 ホスファチジルコリンの製造法
DE4039996A1 (de) 1990-10-31 1992-05-07 Nattermann A & Cie Verfahren zur herstlelung von phosphatidylcholinderivaten
JPH07588B2 (ja) 1991-11-21 1995-01-11 関本 博 ポリエン酸誘導体
FR2692262B1 (fr) 1992-06-10 1994-08-05 Adir Nouveaux nicotinates de diacylglycerols, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06253997A (ja) * 1992-09-18 1994-09-13 Fumio Tsukasaki 止水弁付きハンドシャワー装置
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
US5466685A (en) * 1993-05-13 1995-11-14 Johnson & Johnson Inhibition of expression of beta-lactamase using esters of fatty acid alcohols
US5792786A (en) * 1993-08-02 1998-08-11 Commonwealth Scientific And Industrial Research Organisation Non-steroidal anti-inflammatory fatty acid conjugates and their therapeutic use thereof
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
GB9508023D0 (en) 1995-04-20 1995-06-07 Scotia Holdings Plc Fatty acid derivatives
EP0823897B1 (en) * 1995-05-01 2004-07-28 Scarista Limited Nicotinic acid esters and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AR004483A1 (es) 1998-12-16
NO975035D0 (no) 1997-10-31
NO975035L (no) 1997-12-22
IS4603A (is) 1997-10-30
KR19990008244A (ko) 1999-01-25
SK147097A3 (en) 1998-06-03
BG102012A (en) 1998-05-29
NZ306508A (en) 2001-01-26
PL323176A1 (en) 1998-03-16
ES2224166T3 (es) 2005-03-01
NO975036D0 (no) 1997-10-31
JP3960481B2 (ja) 2007-08-15
HUP9802308A3 (en) 1999-12-28
SI0823895T1 (en) 2005-02-28
JP4213205B2 (ja) 2009-01-21
DE69633008D1 (de) 2004-09-02
CA2218699A1 (en) 1996-11-07
HUP9802384A2 (hu) 1999-03-29
DE69633008T2 (de) 2005-08-11
PL187172B1 (pl) 2004-05-31
JPH11504339A (ja) 1999-04-20
EP0823889A1 (en) 1998-02-18
EP0823889B1 (en) 2002-09-18
USRE43632E1 (en) 2012-09-04
PT823895E (pt) 2004-11-30
AU707600B2 (en) 1999-07-15
BR9606604A (pt) 1997-09-16
NZ306509A (en) 1999-06-29
SI0823889T1 (en) 2003-04-30
AU713858B2 (en) 1999-12-09
USRE40480E1 (en) 2008-09-02
BR9606607A (pt) 1998-12-15
MY117596A (en) 2004-07-31
CZ341397A3 (cs) 1998-07-15
EP0823895A1 (en) 1998-02-18
IL118061A (en) 2002-05-23
NO975036L (no) 1997-12-17
PL323152A1 (en) 1998-03-16
KR19990008243A (ko) 1999-01-25
JPH11504914A (ja) 1999-05-11
SK146997A3 (en) 1998-10-07
HUP9802384A3 (en) 1999-06-28
IL118061A0 (en) 1996-08-04
CA2218699C (en) 2009-09-15
MY118354A (en) 2004-10-30
ATE224353T1 (de) 2002-10-15
TR199701276T1 (xx) 1998-02-21
CZ297646B6 (cs) 2007-02-21
EE9700281A (et) 1998-04-15
SK285135B6 (sk) 2006-07-07
BG102011A (en) 1998-05-29
DE69623764T2 (de) 2003-05-28
EE9700275A (et) 1998-04-15
CA2218702C (en) 2008-07-29
DE69623764D1 (de) 2002-10-24
US6555700B1 (en) 2003-04-29
ATE272053T1 (de) 2004-08-15
EP0823895B1 (en) 2004-07-28
EE04462B1 (et) 2005-04-15
PT823889E (pt) 2003-02-28
WO1996034846A1 (en) 1996-11-07
JP2007231020A (ja) 2007-09-13
ES2185772T3 (es) 2003-05-01
CA2218702A1 (en) 1996-11-07
TR199701277T1 (xx) 1998-02-21
WO1996034855A1 (en) 1996-11-07
AU5508096A (en) 1996-11-21
HK1003882A1 (en) 1998-11-13
BG63892B1 (bg) 2003-05-30
RU2215733C2 (ru) 2003-11-10
US6245811B1 (en) 2001-06-12
CZ341497A3 (cs) 1998-08-12
DK0823895T3 (da) 2004-12-06
AU5507996A (en) 1996-11-21
IS4604A (is) 1997-10-30
HUP9802308A2 (hu) 1999-02-01

Similar Documents

Publication Publication Date Title
DK0823889T3 (da) 1,3-propandiolderivater som bioaktive forbindelser
DE69736711D1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
NL300214I2 (nl) Chinazolinederivaten.
DK0888359T3 (da) Pyrimidin-4-on-derivat som pesticid
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DK0869949T3 (da) Benzoxaziner som antimikrobielle midler
TR199600883A2 (tr) Pürin-6-on türevleri.
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
DE69626754D1 (de) Wässrige, vernetzbare Zusammensetzungen
TR199600715A2 (tr) Kefalosforin türevleri.
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
FI972585A0 (fi) Virustenvastaisina aineina käyttökelpoiset tienoksatsinonijohdannaiset
ATE240941T1 (de) 1,25-dihydroxy-16,22,23-trisdehydro- cholecalciferol-derivate
NO962931D0 (no) N,N-Dietyl-8,8-dipropyl-2-azaspiro[4,5Ådecan-2-propanamindimaleat
BR9510036A (pt) Derivados de 1,3,4-oxadiazina
NL1000001A1 (nl) Stal.
DK0770603T3 (da) Alkynylphenylaminosulfonylurinstoffer som herbicider
DE59508591D1 (de) 2-arylcyclopentan-1,3-dion-derivate
FI960599A (fi) 2-oksiminometyyli-1-fenyyli-1,3-propaanidionijohdannaiset herbisideinä
DK0941082T3 (da) Hidtil ukendt anvendelse for 1,3-propandiolderivater
DE59606925D1 (de) 1,6-Naphthyridoncarbonsäurederivate
FI1335U1 (fi) Anordning foer maskinell torkning av organiskt loesmaterial, som straomaterial, torv, traeflis och motsvarande
NO924046L (no) 2[, 3[-dideoksy-4[-tioribonukleosider som antivirusmidler
FI952782A0 (fi) Braennare, i synnerhet foer foerbraenning av flytande braensle och en braensle-vattenblandning